Upcoming Key Date for TherapeuticsMD’s (TXMD) Dyspareunia Treatment TX-004HR
Shares of TherapeuticsMD Inc. (NYSEMKT:TXMD) surged more than 1.5% in after-hours trading Tuesday as the company delivered its quarterly earnings report and said that it will be having a conference call and webcast before the market open on Monday, May 8 to provide a regulatory update on its TX-004HR – an investigational therapy for moderate-to-severe dyspareunia (painful sexual intercourse) in postmenopausal women – based upon its expectation that the U.S. government agency Food and Drug Administration (FDA) will make a decision on the New Drug Application (NDA) for the vaginal softgel capsule by May 7, 2017 – the PDUFA date -.
For the first quarter 2017, TherapeuticsMD posted net revenues of $3.99 million, a 19.2% decrease year over year, and a net loss of ($21.16) million, or ($0.11) per diluted share, compared to a net loss of ($20.93) million, or ($0.11) per diluted share in the same quarter the prior year. According to the Capital IQ Consensus estimate, Wall Street’s analysts were expecting the company to report a net loss of ($0.11) per share on revenues of $5.26 million for the period.
TXMD stock finished the regular session in negative territory by 3.99% (or -$0.20) at $4.81 with a total volume of 5.82M shares traded.
TherapeuticsMD, an innovative women’s healthcare company, has 203.93M shares outstanding, market capitalization (intraday) of $963.58M and TXMD stock 52-week range is from $4.39 to $9.29 per share
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/